16 Jan 2018 Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA
13 Jan 2018 Forty Seven Inc. to Collaborate on a Novel Immuno-Oncology Combination for Leukemia and Bladder Cancer
13 Jan 2018 Roche’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis
11 Jan 2018 First Treatment for MERS Appears Safe in NIH Phase I Clinical Trial
11 Jan 2018 Morphotek Announces FDA Acceptance Of Investigational New Drug Application For Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202
11 Jan 2018 AstraZeneca receives EU approval of Fasenra for severe eosinophilic asthma
09 Jan 2018 InflaRx receives IND acceptance to proceed with a Phase IIb Trial with lead candidate IFX-1 in Hidradenitis Suppurativa
09 Jan 2018 Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Facioscapulohumeral Dystrophy
09 Jan 2018 NeuClone Discloses Details of its Fifth Product: A Biosimilar Candidate for Prolia/XGEVA (Denosumab)
09 Jan 2018 Five Prime Therapeutics Earns IND Milestone Payment Under Immune Checkpoint Pathways Discovery Collaboration with Bristol-Myers Squibb and Announces that BMS has Extended the Research Term of this Collaboration for a Second Time
09 Jan 2018 Aptevo Therapeutics Begins Patient Dosing in Phase 2 Clinical Trial of Otlertuzumab in Peripheral T-Cell Lymphoma
09 Jan 2018 Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab**
09 Jan 2018 Advanced Proteome Therapeutics and Heidelberg Pharma Progress Collaborative Program
08 Jan 2018 Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs
08 Jan 2018 European Medicines Agency Accepts Filing For EVENITY™ (Romosozumab)
07 Jan 2018 FDA Approves XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
07 Jan 2018 Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy Volunteers
04 Jan 2018 ImmunoGen Announces First Patient Dosed in Phase 1 Study of IMGN632 for Hematological Malignancies
04 Jan 2018 Five Prime Therapeutics Submits Investigational New Drug Application for Novel B7-H4 Antibody FPA150
04 Jan 2018 Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection
04 Jan 2018 Merus Provides Clinical Updates for MCLA-117 and MCLA-158 Programs
04 Jan 2018 Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)
03 Jan 2018 Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial
03 Jan 2018 Alligator Bioscience to Receive USD 6 Million Milestone Payment from Janssen Coupled to the Decision to Initiate Combination Trial with ADC-1013
03 Jan 2018 Five Prime Therapeutics Initiates Patient Dosing in Phase 1 Lead-In to Phase 3, Global Registrational Trial of FPA144 in Front-Line Advanced Gastric Cancer

La Merie Biologics

FREE Weekly News Bulletin

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing